Introduction
Nitric oxide (NO) inhibits the growth and induces differentiation of acute myeloid leukemia cells [1, 2] . Expression of human monocyte differentiation markers CD11b and CD14, and tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) transcripts in leukemia cells can be increased by NO [1.2] . Spontaneous NO generating diazeniumdiolate compounds induce apoptosis in acute myeloid leukemia HL-60 and U937 cells [3] , with the long half-life (20 h ) NO donor DETA-NO being the most active. The major obstacle for the use of NO-generating compounds in vivo to treat malignant disease is NO-induced vasodilation [4] . An alternative approach is the use of NO-generating prodrugs that would be activated in the targeted cells, thus avoiding the vascular effects of the drug. For instance, esterase-activated diazeniumdiolates that do not release NO spontaneously but rather are enzymatically activated to release NO are cytotoxic to leukemia cells [5] . However, such a drug design is unlikely to provide enough selectivity because esterases are ubiquitous. Many malignant cells, including leukemia cells, overexpress glutathione S-transferases (GST) which result in resistance to cytotoxic compounds through glutathione (GSH) conjugation and cellular efflux via multi-drug resistance (MRP) pumps, or by inhibition of mitogen activated protein kinases (MAPK) [6] . Consequently, GST constitutes an attractive enzyme system for the targeting of cytotoxic agents to cancer cells. O 2 -arylated diazeniumdiolates are designed to release NO upon conjugation with GSH in a reaction catalyzed by GST. O 2 -(2,4-dinitrophenyl) 1-[(4-ethoxyxarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K), the lead compound from this family is potently cytotoxic to human myeloid leukemia HL-60 cells in vitro and in vivo [7] . JS-K also inhibits hepatoma Hep 3B cell proliferation [8] , enhances arsenic-and cisplatin-induced cytolethality in arsenic-transformed rat liver cells [9] , and induces apoptosis in human multiple myeloma cell lines [10] . In the National Cancer Institute 51-cell panel screen, JS-K was effective against leukemia, renal cancer cells, prostate cancer cells, and brain cancer cells [11, 12] . In in vivo murine models, JS-K was effective in inhibiting the growth of HL-60 (leukemia) [7] , PPC-1 (prostate cancer) [7] , JM-1 (hepatoma) [11] , and OPM1 cells (myeloma) [10] . Consequently, JS-K is a lead compound establishing a new class of cancer chemotherapeutic agents [12] . Mechanisms for the antineoplastic effects of JS-K are not completely elucidated. In HL-60 cells, JS-K induces differentiation and apoptosis. JS-K-induced apoptosis in HL-60 cells occurs through activation of both the intrinsic and extrinsic pathways [7, 13] . Apoptosis induction by JS-K is mediated, at least in part, by cytochrome c release and caspase activation [13] . The goal of the present study was to use microarray and real-time polymerase chain reaction (RT-PCR) analysis to identify genes that are modulated by JS-K in killing HL-60 cells. Confocal image analysis was also performed on selected proteins. Results demonstrate that multiple molecular events are likely involved in the antitumor effects of JS-K, including activation of caspases, modulation of cell growth and differentiation genes, increased expression of anti-angiogenesis genes and genes inhibiting tumor cell migration, all of which could be potential molecular targets for the anticancer effects of JS-K.
Materials and methods

Materials
JS-K was synthesized as previously described [14] . The Clontech Human Cancer Arrays (600 genes) were purchased from Clontech (Palo Alto, CA). All the primers for RT-PCR analysis were synthesized by Sigma-Genosys (The Woodlands, TX). All other chemicals were of reagent grade.
Cell culture and JS-K treatment
Human myeloid leukemia HL-60 cells (ATCC, Manassas, VA) were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin. Cells were cultured at 37°C in a 5% CO 2 humidified atmosphere. JS-K stock (5 mM) was prepared with dimethyl sulfoxide (DMSO) and diluted in phosphate buffered saline (PBS) before addition to cultures. The final concentration of DMSO added to the cultures was less than 0.1% and the media containing 0.1% DMSO was used as controls. JS-K was added to HL-60 cells at concentrations of 0, 0.25, 0.5, and 1.0 μM, and cells were harvested 2, 4, 6, and 24 h later.
RNA isolation
At the end of JS-K treatments, cells were harvested by centrifugation and total RNA was isolated with TRIzol agent (Invitrogen, Carlsbad, CA), followed by purification and DNase-I digestion with RNeasy columns (Qiagen, Valencia, CA). The quality of RNA was determined by the 260/280 ratios, and by gel electrophoresis to visualize the integrity of 18S and 28S bands.
Microarray analysis
Approximately 5 mg of total RNA was converted to [a-32 P]-dATPlabeled cDNA probe using MuLV reverse transcriptase and the Atlas human cancer cDNA synthesis primer mix, and then purified with a NucleoSpin column (Clontech, Palo Alto, CA). The human cancer membrane array (588 genes, Clontech, Palo Alto, CA) was used for analysis. The membranes were prehybridized with Expresshyb from Clontech for 2 h at 68°C, followed by hybridization with the cDNA probe overnight at 68°C. The membranes were then washed four times in 2× SSC/1% SDS, 30 min each, and two times in 0.1× SSC/0.5% SDS for 30 min. The membranes were then sealed with plastic wrap and exposed to a Molecular Dynamics Phosphoimage Screen. Images were analyzed densitometrically using the AtlasImage software (Clontech, version 2.01). Gene expression intensities were first corrected with the external background and then globally normalized as described previously [25] .
Real-time RT-PCR analysis
Total RNA was reverse transcribed with MMLV reverse transcriptase and oligodT primers. The PCR primers were designed with Primer Express software (Applied Biosystems, Foster City, CA, USA) and listed in Table 1 . The Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) was used for real-time RT-PCR analysis. Differences in gene expression between groups were calculated using cycle time (Ct) values, which were normalized against β-actin and expressed as relative to control.
Immuncytochemistry
HL-60 cells were collected by centrifugation and fixed with 3% paraformaldehyde/0.25glutaldehyde in PBS for 10 min, followed by permeabilization with 0.1% Triton X-100 for 10 min at room temperature. After washing with PBS, cells were blocked for 60 min with 1% bovine serum albumin (BSA) in PBS for 30 min, and were incubated at 37°C for 1 h with primary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) diluted with 1%BSA in PBS (1:100). After rinsing 3 times in PBS, secondary antibodies [Alexa Fluor 488 conjugated goat anti-mouse IgG (H+L) (Invitrogen) for TIMP1, MYC and CD14 (1:1000) and Alexa Fluor 543 goat anti-rabbit IgG (H+L) (Invitrogen) for CASP3 (1:500) diluted in PBS containing 1% BSA] were added to the cells and incubated at 37°C for 1 h. Propidium Table 1 Primer sequences for real-time RT-PCR analysis.
Gene
GenBank number Forward Reverse
iodide (1 mg/mL) in 1% BSA was used to stain cell nuclei (1:1000) at room temperature for 10 min. After further washing with PBS, cells were transferred to Teflon imaging chamber for confocal microscopy. Negative controls were treated similarly except they were not exposed to primary antibody. Cells were imaged using a Zeiss LSM 510 laser scanning confocal microscope (Carl Zeiss Inc., Thornwood, NY) with a Zeiss C-Apochromat 40×/1.2 water objective lens. Data reported are the results of single experiments that are representative of three replicate experiments.
Statistical analysis
For microarray analysis, pooled cell samples were performed in triplicate and the mean and SEM were calculated for statistical The base expression levels (control at 6 h) were given in numbers, and were used as The base expression levels (control at 6 h) were given in numbers, and were used as (1.0) to compare with dose-dependent changes. Data are fold changes over controls from average of three hybridizations. ⁎ Significantly different from controls p b 0.05.
analysis [25] ; for RT-PCR analysis, individual samples (n = 3) were used. For comparisons of gene expression between two groups, the Students' t test was used. For comparisons among 3 or more groups, data were analyzed using a one-way analysis of variance, followed by Duncan's multiple range tests. The level of significance was set at p b 0.05 in all cases.
Results
JS-K alters gene expression in HL-60 cells in a concentration-and time-dependent manner
In order to determine gene expression changes, cDNA microarrays were performed following treatment of HL-60 cells with 0.5 μM JS-K for 2, 4, 6, and 24 h (time-course) and at 6 h after treatment with 0, 0.25, 0.5, and 1.0 μM JS-K (dose-response) in triplicates. The expression of approximately 10% or the 600 genes on the human cancer array was significantly altered. Among these significantly altered genes, 20 were selected from the time-course (Table 2 ) and dose-response (Table 3 ) studies. Altered genes included genes related to apoptosis, acute phase protein genes, cell growth regulators, matrix metalloproteases (MMPs), tissue inhibitors of metalloproteases (TIMPs) and others. In general, JS-K-induced gene expression changes occurred in a time-and concentration-dependent manner. The highest changes in gene expression occurred after 24 h treatments; while at the 6 h time-point, the highest concentration (1.0 μM) produced the most significant changes. Thus, HL-60 cells treated with various concentrations of JS-K (0, 0.25, 0.5, and 1.0 μM) for 24 h were further analyzed with RT-PCR for the expression of selected genes based on the potential biological significance. [7, 13] . Consistent with JS-K-induced apoptosis in HL-60 cells (data not shown), the expression of caspase (CASP3) (apoptosis executor) and CASP8 (apoptosis initiator) were increased about 3 fold in JS-K-treated cells (Fig. 1) . In addition to Casp activation, the apoptosis protein gene Casper (data not shown) was also increased 3 fold. Expressions of TNF and IL1B were increased 2.5 and 9 folds, respectively ( Fig. 1 ), in agreement with previous observations of the effects of NO on HL-60 cells [1] . RT-PCR confirmed and extended microarray results. One can therefore conclude that gene expression analysis clearly indicates that apoptotic pathways were activated by JS-K in HL-60 cells.
JS-K induced apoptotic gene expression correspondence to apoptosis in HL-60 cells
JS-K treatment of HL-60 cells induces apoptosis
JS-K induced the differentiation genes in HL-60 cells
An important effect of NO on leukemia cells (including NO generated by JS-K) is the induction of differentiation along the monocytic pathway [1, 2, 7] . Thus, the effects of JS-K on monocytic differentiation markers were examined. As shown in Fig. 2 , JS-K treatment increased the expression of ITGAM and CD14. The increase in CD14 was as high as 19-fold at the highest dose of JS-K. Expression of vimentin (VIM), a gene associated with the late differentiation of HL-60 cells [15] , was also increased by 4.5 folds (Fig. 2) .
JS-K altered the expression of acute phase response genes in HL-60 cells
JS-K is known to activate acute phase proteins such as c-jun and c-fos and MAP kinases in Hep3B hepatoma cells, CAsE cells, and multiple myeloma cells [8] [9] [10] . In microarray analysis, acute phase protein genes EGR1, FGR, MAP kinases (MAPK8), and p53-induced protein LITAF were all increased; while cell growth related genes such as cyclins and insulinlike growth factors (IGFs) were decreased (Tables 2 and 3 ). Real-time RT-PCR (Fig. 3) shows that JS-K increased the expression of TP53, JUN, and EGR1 in a dose-dependent fashion, but decreased the expression of MYC and CCNE1. In HL-60 cells, the expression of MYC had been shown to be depressed by the NO donor sodium nitroprusside and NO gas [1] , and the downregulation of c-myc by valproic acid was associated with HL-60 cell growth arrest [16] .
JS-K increased the expression of genes of anti-angiogenesis and anti-tumor cell migration JS-K has been shown to inhibit angiogenesis in vitro [17] . Thus, we examined the effect of JS-K on anti-angiogenesis gene expression in HL-60 cells. Expression of the anti-angiogenesis gene thrombospodin-1 (THBS1) and its receptor CD36 were significantly increased by JS-K in a concentration-dependent manner (Fig. 4) . One of the interesting findings from the microarray analysis was alterations in expression of matrix metalloproteinases (MMPs) and tissue inhibitor of matrix metalloproteinases (TIMPs) (Tables 2 and 3 ). To confirm microarray findings, the expression of MMP11, TIMP1, TIMP2, and TIMP 3 were examined (Fig. 5) . Consistent with microarray findings, these genes were all upregulated over 3 folds, and up to 6-fold increase in TIMP1 expression was evident. Of note is that TIMP1 plays an antiangiogenesis role in mammalian cells and the inhibition of TIMP1 enhances angiogenesis both in vivo and in vitro [18] .
Confocal imaging analysis of JS-K altered protein expression in HL-60 cells
To verify the above gene expression changes, confocal imaging analysis was conducted to examine the expression and localization of relevant proteins at the cellular levels (Fig. 6) . The intensity of apoptosis executor CASP3 was markedly enhanced, especially in apoptotic cells; the expression of CD14 was also markedly enhanced, mainly in the cytoplasma; while the expression of MYC was attenuated, consistent with mRNA data; and the expression of TIMP1 was universally increased, mainly located in the cytosol of HL-60 cells.
Discussion
This study initially used cDNA microarray to profile gene expression changes produced by JS-K in human leukemia HL-60 cells. Both time-course and dose-response studies showed that JS-K modulated the expression of genes related to apoptosis, cell differentiation, acute phase response, anti-angiogenesis, and tumor cell migration. Realtime RT-PCR and confocal image analysis at the 24 h time point verified the selected key gene expression changes at both transcript levels and the protein levels. Thus, multiple molecular targets are clearly involved in anticancer effects of JS-K.
NO and NO donors have long been recognized to induce human leukemia cell apoptosis and differentiation [1, 2, 7] . The apoptotic effects of NO prodrugs are also associated with acute phase protein/ gene induction (e.g., JUN and FOS) and MAP kinase pathway activation (e.g., JNK and ERK) [8] [9] [10] 19] . The TNF, TP53, and Fas/CD95 pathways, as well as activation of caspase cascades and apoptotic proteins (such as Bad, BAX, and MCL1), are involved in JS-K-induced apoptosis in various tumor cells [7, 10, 13] . The current gene expression analysis clearly demonstrated that JS-K induced apoptosis and apoptosisrelated gene expression are a major mechanism for tumor cell killing.
Induction of human myeloid cell differentiation is an important anti-leukemic mechanism for NO donors, including JS-K [1, 2, 7] . In the present study, the expression of CD14, a marker of monocytic differentiation, was increased up to 19 fold by JS-K, an effect too dramatic to ignore. Expression of CD11b and vimentin was also increased about 4 fold. Both molecules are known to be involved in NO-induced differentiation in HL-60 cells [1, 2, 15] . The induction of leukemia cell differentiation is an important mechanism for JS-K's anti-leukemic properties.
JS-K is known to activate acute phase proteins such as c-jun and cfos and MAP kinases in Hep3B hepatoma cells, CAsE cells, and multiple myeloma cells [8] [9] [10] . In microarray analysis, a number of acute phase protein genes were increased, including p53 and early growth response protein-1 (EGR1). A recent work demonstrates that JS-K inhibition of ubiquitin-activating enzyme E1 activity may preferentially induce apoptosis in p53-expressing tumor cells [20] . In contrast to upregulation of other acute proteins, the expression of MYC, another major acute phase protein, was decreased by JS-K at both transcript and protein levels, together with decreased expression of CCNE1. These effects may be specific for myeloid leukemia cells, as it has been reported that the expression of MYC was decreased by the NO donor sodium nitroprusside and NO gas [1] , and the downregulation of MYC is associated with HL-60 cell growth arrest [16] .
JS-K has been shown to block angiogenesis by inhibiting proliferation, migration, and cord formation in human umbilical vein endothelial cell cultures [17] . This prompted us to examine the expression of anti-angiogenesis genes, and indeed, two of antiangiogenesis protein genes, TSP-1 and its receptor CD36, were significantly increased by JS-K, supporting a role for JS-K as an antiangiogenesis modulator. NO has been shown to have a dual, biphasic response in tumor biology, including the modulation of the gatekeeper THBS1 in tumor angiogenesis [21, 22] . TSP-1 is known to act through its receptor CD36 to inhibit cell proliferation and tumor cell angiogenesis [22] . Activation of THBS1 and CD36 is also an important pathway to initiate tumor cell apoptosis via MAP kinases and to induce p53-mediated cascade with resultant cell growth arrest [23] . It should also be noted that increased expression of TIMP1 in the present study can also exert an anti-angiogenic effect [18, 24] .
Microarray analysis revealed that JS-K increased the expression of MMPs and TIMPs, which was further verified by real-time RT-PCR analysis. In breast cancer cells, induction of TIMP2 and TIMP1 by JS-K is thought to play an important role in JS-K's anti-invasive effects against breast cancer MDA-MB-231, F10, and MCF-7/COX2 cells [25] . MMPs and TIMPS regulate extracellular matrix turnover and remodeling during normal development and pathogenesis. They also play important roles in tumor cell signaling, tumor cell progression, angiogenesis, and tumor metastasis [24] [25] [26] . The dramatic induction of TIMPs by JS-K in HL-60 myeloid leukemia cells is a novel finding, and its contribution to inhibit tumor cell migration and metastasis is worthy of further investigation.
The exact mechanism by which JS-K effects these gene expression changes in acute myeloid leukemia cells are unknown. As a NO generator, JS-K is bound to cause significant oxidative stress with resultant changes in stress response genes. Kiziltepe et al. have also observed that JS-K induces DNA strand breaks in multiple myeloma cells [10] . A similar mechanism is likely at play in myeloid leukemia cells with resultant induction of stress response genes. However, NO delivery to malignant cells is not the only cytotoxic mechanism for JS-K. Arylation of free protein thiols with resultant modification of protein function is also likely to play a role in JS-K's anti-neoplastic effects [11] . Furthermore, Townsend et al. have shown that the JS-K derivative PABA/NO is cytotoxic to ovarian cancer cells through a mechanism involving protein thiol glutathionylation [27] . It is therefore likely that JS-K modulates gene expression through modification of key transcription factors or signaling molecules via arylation and glutathionylation reactions.
In summary, this gene expression analysis revealed several potential mechanisms by which JS-K kills HL-60 cells in a concentration-and time-dependent manner. These mechanisms include activation of the p53-and TNF-α-mediated apoptotic pathways via acute phase responses, activation of the caspase cascade and induction of differentiation in myelogenous leukemia cells. In addition, JS-K induction of anti-angiogenesis gene expression and increased expression of TIMPs suggest a potential effect against tumor cell invasion and metastasis. These results could shed light on molecular targets for anticancer effects of JS-K, a lead O 2 -arylated diazeniumdiolate NO prodrug.
